Meron-Sudai Shiri, Asato Valeria, Adler Amos, Bialik Anya, Goren Sophy, Ariel-Cohen Ortal, Reizis Arava, Mulard Laurence A, Phalipon Armelle, Cohen Dani
School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel.
Clinical Microbiology Laboratory, Tel-Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, 6423906, Israel.
NPJ Vaccines. 2023 Mar 10;8(1):35. doi: 10.1038/s41541-023-00624-y.
Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate.
志贺氏菌是全球中度至重度腹泻的主要病因，也是低收入和中等收入国家5岁以下儿童腹泻相关死亡的主要病因。人们对志贺氏菌病疫苗的需求很高。SF2a-TT15是一种针对福氏志贺氏菌2a（SF2a）的基于合成碳水化合物的结合疫苗候选物，在成年志愿者中被发现是安全且具有强免疫原性的。在此，10µg寡糖（OS）疫苗剂量的SF2a-TT15在接种疫苗后2年和3年随访的大多数志愿者中显示出在强度和功能上诱导持续的免疫反应。接种疫苗3个月后测定的高水平体液参数之一以及特异性IgG记忆B细胞数量是免疫反应持久性的良好预测指标。本研究首次考察了志贺氏菌疫苗候选物诱导的抗体功能和记忆B细胞反应的长期持久性。
